Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $161.00 at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price lowered by Royal Bank of Canada from $165.00 to $161.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. Royal Bank of Canada's price target indicates a potential upside of 59.06% from the stock's current price.

Several other research analysts also recently weighed in on the company. Evercore ISI reduced their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Guggenheim boosted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Robert W. Baird decreased their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price target for the company. Finally, StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $173.52.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded down $5.53 on Thursday, hitting $101.22. The company's stock had a trading volume of 1,354,618 shares, compared to its average volume of 867,523. The company has a market capitalization of $9.67 billion, a price-to-earnings ratio of 80.98 and a beta of 0.75. Sarepta Therapeutics has a 1 year low of $100.14 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a fifty day moving average price of $115.89 and a 200-day moving average price of $122.46.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Manchester Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. lifted its position in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.